- Home
- XERS vs DSGR Comparison
XERS vs DSGR Comparison
Compare XERS & DSGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | DSGR |
|---|---|---|
| Founded | 2005 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | XERS | DSGR |
|---|---|---|
| Price | $8.21 | $34.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | $10.83 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 2.0M | 244.5K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 100.00 | ★ 212.50 |
| EPS | 0.01 | 0.01 |
| Revenue | $49,590,000.00 | ★ $1,980,023,000.00 |
| Revenue This Year | $34.37 | $5.35 |
| Revenue Next Year | $22.86 | $3.79 |
| P/E Ratio | ★ $832.00 | $3,451.00 |
| Revenue Growth | ★ 142.67 | 9.75 |
| 52 Week Low | $4.87 | $19.02 |
| 52 Week High | $10.08 | $34.83 |
Technical Indicators
Market Signals| Indicator | XERS | DSGR |
|---|---|---|
| Relative Strength Index (RSI) | 57.84 | 83.74 |
| Support Level | $8.00 | $26.89 |
| Resistance Level | $8.42 | $34.83 |
| Average True Range (ATR) | 0.34 | 0.31 |
| MACD | -0.09 | 0.56 |
| Stochastic Oscillator | 39.00 | 96.05 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About DSGR Distribution Solutions Group Inc.
Distribution Solutions Group Inc is a specialty distribution company providing value-added distribution solutions to the maintenance, repair and operations (MRO), original equipment manufacturer (OEM) and industrial technology markets. The company operates through four reportable segments: Lawson, TestEquity, Gexpro Services and Canada Branch Division. Lawson distributes specialty products and services to the industrial, commercial, institutional and government MRO marketplace. TestEquity, which generates maximum revenue, distributes test and measurement equipment and solutions, industrial and electronic production supplies and vendor managed inventory programs. Gexpro Services is a supply chain solutions provider. The company generates majority of its revenue from United States.